FDA Agrees with OncoGenex' Phase 3 AFFINITY Protocol Amendment Co-primary Survival Endpoint Included for a Prospectively-Defined Poor Prognosis Subpopulation

BOTHELL, Wash. and VANCOUVER, June 10, 2015 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the U.S. Food and Drug Administration (FDA) has agreed to the Company's proposed amendment to the Phase 3 AFFINITY protocol and statistical analysis plan. The amendment includes the addition of a co-primary endpoint designed to prospectively evaluate the survival benefit of custirsen in men who are at increased risk for poor outcomes when treated with cabazitaxel for metastatic castrate-resistant prostate cancer (CRPC). "There are limited effective treatment options for men with metastatic CRPC who have risk factors for poor outcomes and who fall into a poor...